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Summary Plasminogen activator (PA) is a serine protease which exists in two forms: tissue-type (t-PA) and
urokinase-type (u-PA). The total PA activity was measured in tumour extracts of 235 breast cancer patients
who were followed for a median of 8.5 years after surgery. Patients were initially divided into three groups
with low (<60 unitsmg-' protein), intermediate (60-300 unitmg-' protein), or high (>300 unitmg-'
protein) total PA activity in tumour extracts. The PA activity was not significantly associated with the
recognised prognostic factors of age, menstrual status, tumour size, lymph node involvement, histologic type,
grade of anaplasia, and/or vessel involvement. A significant association was found between total PA activity
and the oestrogen receptor (ER) or progesterone receptor (PgR) status. Among receptor-positive tumours, a
significantly greater proportion of patients had high PA activity in their tumour extracts. Breast cancer
patients with low total PA activity had a significantly shorter disease-free and overall survival rate when
compared to those with intermediate or high PA activity. In univariate and multivariate analyses, total PA
activity (<60 unitmg-' vs >,60 unitmg-' protein) was found to be a significant prognostic factor for
disease-free and overall survival of about the same import as lymph node involvement. Furthermore, the
combination of total PA activity and nodal status could be even more precise in predicting survival times and
probabilities in individual patients. This retrospective study demonstrates the total PA activity is a valuable
prognostic factor in determining prognosis in human breast cancer.
Neoplastic cells are known to express various proteolytic
enzymes, which, in animal models, make them invasive and
favour their dissemination to distant sites (Orenstein et al.,
1983; Persky et al., 1986; Mignatti et al., 1986; Butler et al.,
1986; Reich et al., 1988). Plasminogen activator (PA) is such
a serine protease. Two main forms of PA are known: tissue-
type (t-PA) and urokinase-type (u-PA) (Blasi, 1988). A
number ofinvestigators have suggested that a high activity of
this enzyme in a tumour may destroy peritumoural tissues
(Dano et al., 1985; Colombi et al., 1986). Plasmin degrades
proteins of the extracellular tumour stroma and of the base-
ment membrane (fibrin, fibronectin, laminin) (Duffy, 1987;
Reich et al., 1988) and activates procollagenase IV, which
degrades collagen (Paranjpe et al., 1980). This tumour-
associated proteolysis provides the basis for tumour cell
invasion and facilitates the release and subsequent metastasis
of tumour cells.
We showed previously that in 7,12-dimethylbenz(a)anthra-
cene (DMBA)-induced rat mammary carcinomas and in the
human breast cancer cell line, MCF-7, the total PA activity
of PAs is regulated by oestrogen at a transcriptional level via
an oestrogen receptor system, and pointed out that the total
PA activity may be a useful marker of oestrogen action in
breast cancer cells (Yamashita et al., 1984; Inada et al., 1991;
Inada et al., 1992). Furthermore, we have measured total PA
activity in tissue extracts from human breast cancer and
found that the activity correlates positively with oestrogen
receptor (ER) status (Yamashita et al., 1986). We have now
extended this study and reviewed retrospectively the medical
records of these patients. We show here that patients with
breast cancers containing low levels of total PA activity,
unexpectedly, have significantly shorter disease-free and
overall survival times.
Materials and methods
Patients
The 235 breast cancer patients analysed in this were the same
analysed in a previous study (Yamashita et al., 1986) in
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which the total PA activity in breast cancer tissues was
determined. These patients underwent curative mastectomy in
the Department of Surgery II, Kumamoto University Hos-
pital, during the 4-year period from 1981 to 1984. The
medical records of these 235 patients were evaluated retro-
spectively in this study. The median follow-up period for
patients with a low PA activity was 8.5 years (range,
7.1-10.3 years) and for patients with intermediate or high
levels it was 8.5 years (range, 7.0-10.5 years). Every death in
this study was due to metastatic breast cancer.
The clinicopathologic parameters studied for prognostic
value were age, menstrual status, tumour size, number of
positive nodes, histologic type, histologic grade, vessel
involvement, ER, Progesterone receptor (PgR) and total PA
activity. Tumour size was measured as the greatest diameter
of the tumour. The extent of lymph node metastasis was
categorised into one of three groups: 0, 1 to 3 and 4 +. Each
tumour was typed according to the classification of the Japan
Mammary Cancer Society (9th edition, 1988) and was graded
in parallel according to the criteria described by Bloom and
Richardson (1957). In this series, 228 of the tumours were
invasive ductal carcinomas and seven were non-invasive duc-
tal carcinomas. Every histological analysis was made by the
same author (J.Y.).
Assayfor total PA activity
Frozen tissue was homogenised and extracted with 50 mM
Tris-HCI buffer (pH 7.4) containing 0.25% Triton X-100, as
described previously (Yamashita et al., 1984). Total PA
activity was determined as described previously (Yamashita
et al., 1984) in a coupled assay using S-2251 (H-D-Val-Leu-
Lys-pNA, Kabi, Stockholm) as a substrate for plasmin. Total
PA activity determined in this study represented a mixutre of
t-PA and u-PA activities.
Assayfor hormone receptors
ER and PgR were determined by the dextran-coated charcoal
method as described previously (McGuire et al., 1977).
Tumour specimens were considered hormone receptor-
positive if they contained at least 10 fmol specific binding
sitesmg-' protein.
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Statistical analyses
The BMDP Statistical Package (BMDP Statistical Software,
Inc., Los Angeles, CA.) program (Dixon, 1985) for the com-
puter (IBM 4381; IBM, New York) was used for all analyses.
The BMDP P4F program was used to perform the chi-square
test to compare the data among groups of patients. Analyses
of disease-free and overall survival were performed using the
Kaplan-Meier method (Kaplan & Meier, 1958) in the BMDP
PIL program. Tests of differences between curves were made
with the log-rank test (Mantel, 1966) for censored survival
data. The BMDP P2L program was used for Cox analysis
(Cox, 1972) to evaluate various combinations and inter-
actions of prognostic factors in a multivariate manner.
Results
Two hundred thirty five patients were classified into one of
three groups according to low, intermediate, or high total PA
activity in their breast cancer tissue. The cut-off points of the
lower and upper quartiles of the distribution of total PA
activity were identified by the method of Thorpe et al. (1989)
for this classification scheme. The low-intermediate and
intermediate-high cut-off points were identified to be 60 and
300 unitmg-' protein, respectively. Of 235 patients, 53 had a
level of PA activity which was less than 60 unit mg 'protein,
101 had intermediate, and 81 had levels of PA activity
greater than 300 unit mg-' protein. We then investigated
whether total PA activity (low, intermediate, high) may be
associated with recognised prognostic factors. As Table I
shows, there is not significant association between PA
activity level and age, menstrual status, tumour size, number
Table I Correlation between PA activity and other prognostic
parameters
Parameters n Chi-squared P-value
Age 1.262 0.77
<50 yr 94
> 50 yr 141
Menstrual status 1.804 0.69
premenopause 113
postmenopause 122
Tumour size 1.772 0.86
<2cm 43
2-5 cm 132
>5cm 60
Node involvement 3.145 0.53
0 79
1-3 84
>4 72
Histologic type 2.403 0.91
papillotubular 52
solid-tubular 93
scirrhous 83
others 7
Histologic grade 4.981 0.40
Grade I 72
Grade II 89
Grade III 74
Vessel involvement 1.917 0.68
absent 123
present 112
ER 6.339 0.05
positive 127
negative 108
PgR 9.560 0.01
positive 88
negative 147
Two hundred thirty five patients were categorised according to total
PAactivityintooneofthreegroups: low(<60),intermediate (60-300),
orhigh(>300)PAactivity. Thenumberofpatientsineachgroupareas
follows: low, 53; intermediate, 101; and high, 81.
of positive nodes, histologic type, histologic grade or vessel
involvement. Only the ER and PgR positivity were associated
with a high level of PA activity (P = 0.05, P = 0.01, respec-
tively). This was not surprising, since total PA activity is
increased by oestrogen in breast cancer cells and this result is
consistent with our previous reports (Yamashita et al., 1986).
While total PA activity does not appear to correlate
significantly with most known prognostic factors, disease-free
and overall survival are observed to differ according to the
PA activity status in primary breast cancer tissues. As shown
in Figure 1, patients with breast cancer tissue containing a
low level of PA activity had a significantly shorter disease-
free survival (P = 0.005) and overall survival (P = 0.018) time
than patients with a high or intermediate level of enzyme
activity. With respect to the proportion receiving adjuvant
endocrine therapy or adjuvant chemotherapy, there was no
significant difference among three groups of patients (Table
II). The three groups of patients had similar adjuvant
therapies during the first 2 years after their operation. Table
III shows the correlation between total PA activity and
recurrence in human breast cancer in terms of the pattern of
adjuvant therapy. At any adjuvant therapy group, patients
with tumour containing low PA activity tended to have
higher recurrence rate.
For the reason that low PA activity (<60 unit mg-' pro-
tein) was associated with a significantly poor prognosis in
disease-free and overall survival times, the remaining analyses
were performed using a cut-off point of 60 unit PA
activitymg'1 protein. Table IV shows, in a univariate man-
ner, the relative risk of disease recurrence and death for
different parameters. As can be seen, a low total PA activity
was one of the highest risk factors for recurrence and death.
For low PA activity (<60 unitmg-' protein) and high PA
activity ( > 60 unitmg-' protein), the relative risks of
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Figure 1 Disease-free and overall survival curves among breast
cancer patients according to total PA activity in the tumour
extracts. Following are the number of patients in each group:
>300 unitmg-' protein, 81; 60-300 unit mg ' protein, 101; and
<60 unit mg-' protein, 53.
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Table II Comparisonamongadjuvanttherapiesgiven to breastcancer
patients according to total PA activity
PA activity (unit mg-' protein)
Intermediate
Treatment Low (<60) (60-300) High (>300)
Chemotherapy 5 (12.2%) 11 (12.4%) 9 (13.2%)
Tamoxifen 15 (36.6%) 31 (34.8%) 20 (29.4%)
Chemotherapy + 19 (46.3%) 47 (52.8%) 35 (51.5%)
Tamoxifen
No therapy 2 (4.9%) 0 (0%) 4 (5.9%)
Table III Relationship between total PA activity and recurrence in
human breast cancer in terms of the pattem of adjuvant therapies
PA activity (unitmg-'protein)
Intermediate
Treatment Low (<60) (60-300) High (>300)
Chemotherapy 2/5 (40.0%) 2/11 (18.2%) 1/9 (11.1%)
Tamoxifen 6/15 (40.0%) 5/31 (16.1%) 3/20 (15.0%)
Chemotherapy + 7/19 (36.8%) 9/47 (19.1%) 8/35 (22.9%)
Tamoxifen
No therapy 1/2 (50.0%) 0/0 (0%) 0/4 (0%)
Values in parentheses are the percentage ofpatients with recurrence.
recurrence and death were 3.7 and 5.1, respectively. The
importance of PA activity, as a prognostic marker, was
approximated that of node status but was more important
than either tumour size or histologic grade. Furthermore, in
the multivariate analysis of these four parameters (Table V),
PA activity was a significant predictor of recurrence and
death which was independent of the other three factors. In
the multivariate analysis, neither tumour size nor histologic
grade were related significantly to disease recurrence or
death.
The independence and the additional importance of total
PA activity as a prognostic factor relative to lymph node
status are also illustrated in Figure 2, where low PA activity
identified subgroups with poorer disease-free and overall sur-
vival among both lymph node-negative and lymph node-
positive groups of patients (P = 0.04 in both lymph node
involvement categories).
Discussion
The present study offers statistical evidence that total PA
activity in primary breast cancer tissues is a useful prognostic
marker which identifies clearly high and low risk patients. A
subgroup of patients with a high risk for recurrence was
identified in node negative cancer patients which are usually
considered to have a good prognosis. On the other hand, in
node positive patients considered to be at high risk for
recurrence, a subgroup was identified which had a more
benign outcome.
There are two types of PAs: the urokinase type (u-PA) and
the tissue-type (t-PA). While both catalyse cleavage of the
peptide bond between Arg-Val in plasminogen, thus conver-
ting the proenzyme to plasmin, they differ in many aspects of
their molecular weight, immunological reactivity and amino
acid sequence (Blasi, 1988). The two activators seem to be
involved in different functions. u-PA is supposed to be a key
enzyme in the breakdown of extracellular matrix proteins
during tissue destruction in a variety of normal and
pathological conditions, including the invasive growth and
metastasis of cancer cells, while t-PA is thought to be
involved primarily in thrombolysis. Abundant experimental
evidence supports the belief that u-PA participates in tumour
invasion and metastasis. In an experimental murine tumour
model, Skriver et al. (1984) found by immunohistochemistry
that u-PA was localised to areas of invasive growth and
adjacent degraded tissue. Ossowski and Reich (1983) showed
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Figure 2 Disease-free and overall survival among breast cancer
patients according to lymph node status and total tumour PA
activity. The cut-off point between high and low PA activity is 60
unit mg protein. n( + ) and n( - ) refer to the status of lymph
node metastasis. Following are the number of patients in each
group: high PA/n( -), 59; low PA/n(- ), 20; high PA/n( +),
123; and low PA/n( + ) , 33.
Table IV Relative risk ofdisease recurrence and death associated with
different parameters in breast cancer patients (Univariate analysis)
Disease recurrence Death
Parameters Relative risk P-value Relative risk P-value
Age 1.2 0.42 1.4 0.13
Menstrual 1.4 0.39 1.3 0.704
status
Tumour size 1.7 (1.3-3.1)a 0.045 3.3 (1.5-6.2) 0.0022
Nodal status 3.9 (2.1-7.3) 0.0001 4.5 (1.4-9.7) 0.0004
Histologic 2.1 0.34 2.4 0.62
type
Histologic 1.4 (1.0-4.2) 0.0019 1.9 (0.8-5.1) 0.0055
grade
Vessel 1.5 0.706 1.3 0.81
involvement
ER positivity 1.9 0.075 2.5 0.101
PgR positivity 2.2 0.06 2.4 0.071
PA activityb 3.7 (1.5-6.2) 0.0005 5.1 (1.7-8.5) 0.0005
aValues inparentheses represent95% confidenceintervals; 'The total
PA activity cut-off point was 60 unitmg-' protein.
that antibodies against u-PA, but not those against t-PA,
inhibit cancer cell invasion and metastasis after transplanta-
tion of Hep-3 tumour cells into chicken embryos. This sug-
gests also that u-PA is important in tumour cell invasion and
metastasis. Furthermore, several enzymatic and immunomet-
ric assays performed on human tissues have demonstrated
high u-PA (but not t-PA) activity in malignant tumours,
when compared to their non-neoplastic counterparts, sugges-
ting that u-PA is the dominant in cancer and that t-PA is
unlikely to play a role in cancer spread (Evers et al., 1982;
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Table V Multivariate analysis oftumour size, node status, histologic
grade, and total PA activity as prognostic parameters in breast
cancer
Disease recurrence Death
Parameters Relative risk P-value Relative risk P-value
Tumour size 1.3 NSa 1.5 NS
Node status 2.8 (1.3-4.9)b 0.003 3.3 (1.6-6.8) 0.035
Histologic 1.01 NS 1.43 NS
grade
PA activityc 3.1 (1.5-7.1) 0.003 3.9 (2.1-7.3) 0.001
ThemultivariateanalyseswereperformedwithCox'smodel.aNS: not
significant. bValues in parentheses represent 95% confidence intervals.
CThe total PA activity cut-off point was 60 unit mg-' protein.
Several reports (Duffy et al., 1988a; Janicke et al., 1989;
Duffy et al., 1990; Janicke et al., 1990) have suggested that
patients with high level of u-PA antigen or activity have a
significantly shorter disease-free survival and that u-PA could
be used as a new prognostic marker in human breast cancer.
Duffy et al. (1988a; 1988b; 1990) reported that in breast
cancer u-PA correlates with poor prognosis in breast cancer
and t-PA correlates with good prognosis, and that measure-
ment of total PA activity, therefore, has no prognostic value.
In this regard, our results are inconsistent with the finding of
Duffy et al. (1988b) that total PA activity can not be a
prognostic marker in breast cancer. The differences in these
results may be accounted for partly by differences in the
follow-up period for patients. The median follow-up period
for patients in our study (8.5 years) was much longer than
that in the cited studies in which the median follow-up period
was 19 months (Duffy et al., 1988a), 35 months (Duffy et al.,
1990), 12.5 months (Janicke et al., 1989; Janicke et al., 1990),
or 26 months (Duffy et al., 1988b). In our study, there is not
statistically significant difference at up to 22 months both in
disease-free survival and overall survival.
Our results show that a high total PA activity in primary
breast cancer tissue indicates a good prognosis. This may be
related to the fact that t-PA is an estrogen-inducible enzyme
and that is present when the total PA activity is high
(Dickermann et al., 1989; Mizoguchi et al., 1990; Uchiumi et
al., 1991; Yamashita et al., 1992). The presence of the ER
itself in breast cancer is generally thought to be associated
with a good prognosis (Foekens et al., 1989), although in our
study the prognostic value of ER (P = 0.075) and PgR
(P = 0.06) only approached significance (Table IV). Thus, the
utility of total PA as a marker for good prognosis in breast
cancer may be related to the fact that t-PA is estrogen-
inducible and thus reflects an intact ER system. Until now,
we have determined t-PA and u-PA activities in 144 human
breast cancer specimens using the monoclonal antibodies to
human t-PA and u-PA and showed a greater proportion of
total PA activity is composed of t-PA (84.5-96.3%) (unpub-
lished data). The fact that our assay for total PA activity is
biased towards t-PA may support above assumption.
Treatment is an important confounding factor. Although
the three groups of patients studied had similar adjuvant
therapies (Table II), it would appear likely that patients
whose tumours contain a high level of PA activity could do
better because they responded to endocrine therapy as sug-
gested by Mira-y-Lopez et al. (1991). In addition, since
tamoxifen and chemotherapy are not equally effective in
younger or older women, both of these factors must be
included in any consideration of the interaction between total
PA activity and outcome. However, with only 235 patients in
the total sample, the analysis of multiple subsets is likely to
provide spurious results. Although our results showed the
tumours of patients who had relapsed had lower PA activity
regardless of the pattern of adjuvant therapy, further studies
are necessary in this respect.
Unexpectedly, primary breast cancer patients with low
total PA activity had a poor prognosis. The reason for this
results is not known. Recently however, several lines of
evidence have shed light on this question. Sumiyoshi et al.
(1991) and Reilly et al. (1990) have reported that high levels
of not only u-PA antigen but also high levels of plasminogen
activator inhibitor-I (PAI-1) antigen, a fast and specific
inhibitor of PAs, were found in the majority of breast cancer
tissues and that the levels of both antigens correlate
positively with progression in breast cancer. Of interest was
finding that a significant positive correlation exists between
u-PA and PAI-1 antigen levels and signs of progression of
breast cancer, such as lymph node involvement. Although the
mechanism by which u-PA and its inhibitor, PAI-1, are
co-expressed in aggressive breast cancer is not known, these
results raise the possibility that the low total PA activity in
breast cancer with poor prognosis might be due to co-
expression of u-PA and PAI-I and to the lack of estrogen-
inducible t-PA. As our assay is biased towards t-PA, when
total PA is high t-PA is high. In breast cancer tissues con-
taining high t-PA activity, PAI-i might not be sufficient to
inhibit abundant t-PA activity.
In conclusion, it is obviously necessary to evaluate tissue-
type and urokinase-type components of total PA activity and
to examine PAI-i levels in our series which may clear up the
unexpected results in this report. However, this is the first
report showing that patients with low total PA activity have
a poorer prognosis than do those with high PA activity and
that total PA activity is a significant prognostic factor in
patients with breast cancer. After surgery, breast cancer
patients with low tumour PA activity should be followed
carefully in case effective pharmacotherapy becomes avail-
able.
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